- Investigator
- Michael D Schweitzer Barrios
- Ages
- 40 Years - 80 Years
- Sexes
- All
Clinical trials
-
Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY) -
Double Blind Placebo-Controlled Parallel Group Study of Safety and Efficacy of Isomyosamine in Treating Sarcopenia After Hip or Femoral Fracture in Gerontological Population - Investigator
- Porter F Young
- Ages
- 60 Years - 85 Years
- Sexes
- All
-
VANTAGE study - Investigator
- Neha Agrawal
- Ages
- 18 Years - NA Years
- Sexes
- All
-
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of Asapiprant in Hospitalized Adults With COVID-19 - Investigator
- Carmen Isache
- Ages
- N/A
- Sexes
- All
-
A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PFI) (Also Known as Ledderhose Disease) - Investigators
- John S Anderson, Jason A Piraino
- Ages
- 18 Years - N/A
- Sexes
- All
-
ReMEDy2: A Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke - Investigators
- Benjamin T Alwood, Scott L Silliman
- Ages
- 18 Years - 90 Years
- Sexes
- All
-
ReMEDy2: A Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke - Investigators
- Benjamin T Alwood, Scott L Silliman
- Ages
- 18 Years - 90 Years
- Sexes
- All
-
Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia - Investigator
- Mohammad Ilyas
- Ages
- 0 Years - 12 Years
- Sexes
- All